Abstract: Merkel cell carcinoma (MCC) is a rare, aggressive skin malignancy that has a propensity for local recurrence and metastasis to the lymph nodes. In this case report, we discuss a 54-year-old female with rheumatoid arthritis (RA) who had received treatment with prednisone (15 mg/day) for symptom relief and management. The patient visited our hospital with complaints of a nodule in right preauricular area. Computed tomography (CT) scans revealed no distant metastasis. The patient underwent surgical resection and histopathological evaluation of the nodule led to the diagnosis of MCC. The patients received post-surgical treatment with 6 MeV electronic wire radiotherapy. Six months later, CT of the head, neck, abdomen and chest demonstrated a right cervical lymph node mass at the C2 level. The patient then underwent cervical lymph node biopsy and pathological diagnosis confirmed metastatic MCC. One month after the lymph node biopsy, the patients received postoperative intensity modulated radiation therapy in the biopsied area. The patient did not experience any adverse effects to the therapy. In conclusion, the MCC patients with RA can tolerate radiation therapy. As MCC is a highly malignant neoplasia, considering the immune checkpoint inhibitors can lead to immune-related adverse events, detection of MCC at earlier stages is associated with better survival. The treatment decisions of MCC patients with RA continues is still challenging.
Introduction
Merkel cell carcinoma (MCC), also termed trabecular carcinoma, was initially described in 1972 by Toker. 1 The clinical features of symptomatic and asymptomatic MCC include; rapid expansion (,3 months), immune suppression, patient .50 years and UV-exposed site on fair skin. 2 MCC cells express neuroendocrine markers such as Synaptophysin (Syn) and Cytokeratin 20 (CK20).
3 CK20 is a fairly specific and sensitive marker of MCC, with a characteristic paranuclear dot-like positivity.
MCC has a propensity for widespread metastases and commonly occurs on sun exposed areas of the head and neck. Biologically, MCC is characterized by local recurrence (30%), regional lymph node metastases (65%) and distant metastases (40%). Surgery is the primary treatment strategy for patients with MCC. Wide surgical excision of the primary lesion is the treatment of choice, while the role of prophylactic regional lymphadenectomy is controversial. 4 Adjuvant radiotherapy and chemotherapy is frequently associated.
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Case report
A 54-year-old female patient was admitted for cutaneous and subcutaneous nodule of right preauricular area. She had no history of smoking, alcohol use, blood transfusion, travel abroad or raw meat intake. Twenty-seven years earlier, she had suffered polyarthralgia, morning stiffness in multiple joints and joint swelling of the wrists, knees and feet. Immunology tests revealed that the patient was positive for antinuclear antibodies, rheumatoid factor and cyclic citrullinated peptide at the time of diagnosis. The patient was diagnosed with rheumatoid arthritis (RA) (Steinbrocker classification: stage I, class II), with an unknown Disease Activity Score-28 (DAS28) and received symptomatic treatment (the specific treatment was unknown). Subsequently, she achieved remission of the symptoms, but the symptoms of joint pain and swelling reoccurred, and the patient received treatment with 15 mg/day prednisone. The symptoms and activity of RA were reduced and stable for ten years. Six months post-surgery, the patient was admitted to hospital for review. The general condition of the patient according to Eastern Cooperative Oncology Group 
Discussion
MCC is an uncommon neuroendocrine carcinoma of the skin. MCC has a highly prevalent local recurrence and metastases (including liver, lung, cardiac, bone, pancreatic and other organs). [5] [6] [7] [8] [9] MCC is more frequent in immunosuppressed patients. Immune surveillance plays a critical role in the control of tumour growth and progression. 10 Moreover, immunosuppressive conditions (including HIV infection, 11 solid organ transplantation, 12 lymphoma, 13 and autoimmune disease) 14 are associated with an increased risk of MCC development. Chronic inflammatory disorders increase the risk of MCC significantly, and patients with chronic inflammatory disorders are at higher risk for aggressive MCC.
14 Indeed, connective tissue diseases are also associated with higher incidence of MCC and show poorer MCC-specific survival. 14, 15 Connective tissue diseases include RA systemic lupus erythematosus (SLE), systemic sclerosis (SSc), scleroderma, polymyositis-dermatomyositis and vasculitis. MCC in a patient with rheumatoid arthritis is very rarely reported in literature. Furthermore, there is debate about whether patients with connective tissue diseases can tolerate radiation. Many treatment strategies have been considered for patients with connective tissue diseases such as reducing dose prescription, avoiding concomitant treatment and improvement of radiotherapy technology. 16 As mentioned previously, MCC has a highly prevalent local recurrence and distant metastasis. The anti-programmed death-1 (anti-PD-1) antibody, pembrolizumab, is a systemic therapy option for patients with advanced stage MCC. 4 Furthermore, Avelumab, an anti-programmed death ligand-1 (anti-PD-L1) monoclonal antibody, is a second line therapy for patients with stage IV MCC that progressed following cytotoxic chemotherapy. 17 Previous studies have demonstrated that anti-PD-1/PD-L1 can lead to immune-related adverse events, which could be lethal. [18] [19] [20] [21] T cells are major players involved in the pathogenesis of RA and increasing serum soluble PD-1, which has been reported in RA patient. 22, 23 Furthermore, soluble PD-1 can enhance T cell responses by interfering with PD-1/PD-L1 pathway in autoimmune and tumor. [24] [25] [26] Glucocorticoids (eg, prednisone) are anti-inflammatory 
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Li et al and immunosuppressive agents that are able to reduce the inflammation and the progression of RA. However, it was reported that a baseline corticosteroid use of 10 mg of prednisone or equivalent was associated with poorer outcome in non-small-cell lung cancer patients treated with immunotherapy. 27 And prudent use of corticosteroids at the time of initiating immunotherapy is recommended. 27 Considering the involvement of activated T cells and the development of immune-related adverse events in anti-PD-1 antibody therapeutics. In this case, clinicians should be aware of the possibility of anti-PD-1/PD-L1-related adverse effects, such as inflammatory arthritis, 28 especially in patients with RA. In this case report, the patient with RA tolerated radiation therapy without any adverse side effects. As with MCC of other areas, metastasis or local recurrence can occur after a certain period. Chemotherapy might be a therapeutic option in chemo-sensitive metastatic MCC, and further evaluation is warranted.
Therefore, clinicians should be aware of the use of immune checkpoint inhibitors in MCC patients with RA. We presented a unique case of MCC metastatic to cervical lymph node in a patient with RA. We aim to highlight that the treatment decisions to patients with RA continues to be challenging.
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